Introduction
Hepatocellular carcinoma (HCC), the most common type of liver malignancies, is the third leading cause of cancer-related deaths worldwide [
1]. Due to its concealed onset and rapid progression, HCC often develops to huge tumor burden, vascular invasion, and extrahepatic metastasis at time of diagnosis [
2]. Traditional systemic platinum-based chemotherapy presents unsatisfactory efficacy and is not recommended in the treatment of late-staged HCC [
3]. Recently, several studies confirmed the effectiveness of oxaliplatin-based chemotherapy for improving survival in unresectable HCC patients [
4‐
7]. However, limited by the essentially strong ability of proliferation, metastasis, and drug resistance of HCC cells, some patients still present rapid progression after oxaliplatin therapy [
8]. Thus, there is an urgent need to elucidate the mechanism of HCC progression and chemotherapy resistance, to find effective biomarkers to predict prognosis and improve treatment strategies.
Long non-coding RNAs (lncRNAs), defined as transcripts of more than 200 nucleotides that are not translated into proteins, have been associated with diverse functions [
9]. To date, there has been an explosion of research focused on investigating the role of multiple lncRNAs in regulating proliferation, migration, expansion, and immortality of malignancies [
10,
11]. Despite the elucidation of potential mechanistic roles, the biological relevance of the vast majority of lncRNAs remains uncertain [
12]. Especially, the relationship between lncRNAs and cancer therapy resistance has received increased attention due to the complicated interaction network [
13]. Take several well-known lncRNAs in HCC as examples, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was investigated to promote tumor metastasis and resistance to 5-FU, DOX, and mitomycin [
14]. Moreover, highly upregulated lncRNA in HCC (HULC) suppresses tumor proliferation and invasion, and upregulates the chemosensitivity of oxaliplatin, 5-FU and pirarubicin by inducing autophagy pathway [
15]. This compelling evidence inspired us to explore the mechanisms of lncRNAs on regulating tumor progression and chemosensitivity in HCC.
Terminal differentiation-induced non-coding RNA (TINCR) is one of the most highly induced lncRNAs during epidermal differentiation [
16]. It has been reported to be involved in the progression of many cancers [
17]. Recently, TINCR was indicated to strengthen cisplatin resistance of nasopharyngeal carcinoma [
18]. However, in HCC, the cognition of biological regulation mechanism of TINCR is limited, and its influence on chemosensitivity to oxaliplatin remains unknown.
In this study, we identified that TINCR is upregulated in HCC tissues and associated with poor patient prognosis. Further functional experiments showed that TINCR promotes HCC cells proliferation, invasion, metastasis, and oxaliplatin resistance. As a competing endogenous RNA (ceRNA), TINCR sponges miR-195-3p to increase ST6GAL1 expression and activate the nuclear factor kappa B (NF-κB) pathway. Our study elucidates that TINCR act as a promising biomarker and the regulatory mechanism provides potential therapeutic targets for HCC patients.
Materials and methods
Clinical specimens
The tumors and normal liver tissues were obtained from HCC patients who received hepatectomy in Sun Yat-sen University Cancer Center (SYSUCC). Detailed clinicopathological data were collected according to patient medical records. The long-term follow-up interval was from June 2010 to December 2020. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki, and approved by the Institutional Ethical Review Board of the SYSUCC (B2019–057-01).
Cell culture
The human HCC cell lines (HepG2, HuH7, MHCC-LM3, MHCC-97H, MHCC-97 L, PLC/PRF/5, SK-HEP-1, Hep3B, SMMC-7721, SNU-449) were cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (Gibco) in an incubator sustaining an atmosphere of 5% CO2 and 37 °C. All the cell lines were purchased from the Cell Lines Service (Cellcook Biotech Co., Ltd., Guangzhou, China).
Total RNA was purified using Trizol (Invitrogen) or RNA quick purification kit (ESscience, China). Reverse transcription was performed using miRNA 1st Strand cDNA Synthesis Kit (Vazyme) with Bulge-Loop miRNA-specific RT primers (RiboBio) for miRNA or random primers (Promega) for mRNA and lncRNA. The primers used in qRT-PCR are listed in Supplementary Table S
1. The relative expression level was compared with that of β-actin and fold changes were calculated using the 2
-△△ct method.
Transient transfection and stable transfection of cell lines
Lipofectamine 3000, RNAiMAX, or Opti-MEM I reagents (Invitrogen) were used for transient transfection. The siRNA targeting TINCR, ST6GAL1 were synthesized and purchased from GenePharma. The sequence of TINCR, ST6GAL1, and nonsensical fragment were synthesized and cloned into pcDNA3.1 by Umine Biotechnology Co., LTD (Guangzhou). The mimics and inhibitors of miR-195-3p were designed and supplied by RiboBio. Stably transfected cell lines were constructed and purchased from Obio Technology Corp. All the sequence is listed in Table S
2. Conventionally, transfection systems were co-cultured with targeted cells for 12 h, and then changed to normal medium.
Total RNA of HepG2 cells transfected with anti-TINCR siRNAs was extracted to perform RNA sequencing by PGEM Biotechnology Co., Ltd. (Guangzhou). Differentially expressed genes and microRNAs were identified, and were conducted with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis using the DAVID software. Gene set enrichment analysis (GSEA) was performed through GEO Common Dataset to identify biological functions enriched in HCC with TINCR knockdown. A threshold of P < 0.05 and an FDR ≤ 0.25 were used to select significant items.
Cell proliferation and oxaliplatin sensitivity assay
Transfected cells (2 × 103) were seeded in 96-well plates, and cell viability was detected every 24 h for 5 days using cell counting kit-8 (cck-8) (Glpbio). In the colony formation experiment, transfected cells (4 × 102) were seeded in 6-well plates with and incubated for 14 days, and then fixed, stained, and counted. In addition, the cells were incubated with oxaliplatin (0, 0.5, 1, 2, 4, 8, 16, and 32 μg/ml) for 72 h and then tested for cell viability. In apoptosis assay, the cells were incubated with oxaliplatin at the right concentration for 24 h and then collected for flow cytometry assay.
Flow cytometry assay
Transfected cells were digested with 0.25% trypsin and washed twice with PBS, adjusting to a concentration of 1 × 10.6 Next, 10 μl of Annexin V-FITC and 10 μl propidium staining solution (ESscience, China) were mixed and added to a 0.1 ml cell suspension and incubated at room temperature for 5 min in the dark. Apoptosis was detected by flow cytometry (FACSVantageSE, BD, USA).
In vitro migration and invasion assays
Transwell chambers (Corning) coated without or with matrigel (Corning) were prepared for cell migration and invasion, respectively. Cells (1 × 105) suspended in 200 μl of serum-free medium were seeded in the upper chamber, while 600 μl medium mixed with 10% FBS was added to the lower chamber. After 24 h, the cells that migrated/invaded to the lower surface of the membrane were observed and counted.
Western blotting
Cells were collected and lysed in ice-cold RIPA lysis buffer (Sigma) containing protease and phosphatase inhibitor (Selleck) for 15 min. The supernatant was collected after centrifugation at 14000×g for 15 min. The protein concentration was determined using a BCA protein quantification kit (Beyotime). Then, 30 μg of total protein was added to a 10% SDS-PAGE gel and transferred to a 0.25-μm PVDF membrane (Bio-Rad). The PVDF membrane was blocked with 5% skim milk for 1 h at 37 °C. Next, the membrane was incubated with primary antibodies against GAPDH (Abcam, ab8245), ST6GAL1 (Proteintech, 14,355–1-AP), IκBα (Cell Signaling Technology, no.4814), p-IκBα (Cell Signaling Technology, no.2859), p65(Cell Signaling Technology, no.3031), p-p65(Cell Signaling Technology, no.3033) overnight at 4 °C. After incubation with horseradish peroxidase (HRP)-labeled secondary antibodies at 37 °C for 30 min, the bands were detected using enhanced chemiluminescence (GBCBIO, China) with the ChemiDoc MP Imaging System (Bio-Rad).
Luciferase reporter assays
The wild-type or mutant fragment of TINCR or ST6GAL1 containing the predicting binding sequence of miR-195-3p was subcloned into a psiCHECK2 Dual-luciferase vector (Promega). To verify the target genes of miRNAs, HCC cells were co-transfected with luciferase reporter plasmids and miR-195-3p mimics or negative control. Luciferase activity was measured using the dual-luciferase reporter assay system (Promega). Renilla luciferase expressed by pRL-PGK (Promega) was used as an internal control to correct for differences in both transfection and harvest efficiency.
RNA pulldown
The biotin-labeled miRNA pull-down assay was performed using the RNA Pulldown Kit (BersinBio, Guangzhou, China). Briefly, cells were transfected with biotin-labeled miR-195-3p and miR-ctrl (RiboBio, 50 nM), and lysed after 48 h incubation. Simultaneously, 25 μg streptavidin magnetic beads were mixed with sample lysates and incubated with rotation overnight at 4 °C. Beads were then washed to remove unbound materials. RNA was eluted, isolated, and subjected to qRT-PCR analysis.
Mouse xenograft models
BALB/c nude mice (4–5 weeks old, female) were provided by Guangdong Animal Experiment Center. For tumor growth model, sh-TINCR and scrambled control cells (4 × 106) were resuspended in 100 μl PBS containing 10% matrigel (Corning), and then subcutaneously injected into either side of the posterior flank of the same mouse. When tumor volume reached approximately 100 mm3, the mice were randomly divided into four groups (n = 7), and intraperitoneally injected with normal 5% glucose solution or oxaliplatin (Selleck, 3 mg/kg) every 3 days. Tumors were measured every 3 days from the start of dosing. On day 24, mice were sacrificed and tumors were detached for further measurement and immunohistochemistry detection. All animal experiments complied with the 1978 National Institutes of Health guide for the care and use of laboratory animals. The animal procedures were approved by the Institutional Animal Care and Use Committee of SYSUCC (L102042019110H).
Immunohistochemical (IHC)
Paraffin-embedded tumor tissues were cut as 5-μm sections and processed for IHC. Tissue sections were prepared for antigen retrieval using microwave treatment in citrate buffer (pH 8.0, Beyotime) and then incubated with anti-ST6GAL1 antibody (Proteintech, 14355–1-AP) overnight at 4 °C. Immunostaining was performed using the Envision Inspection System with diaminobenzidine as substrate (DAKO Cytomation, Glostrup, Denmark).
Statistical analysis
Categorical variables were compared using chi-squared test or Fisher exact test. Difference between groups was determined by the Student’s test for one single comparison, and by the ANOVA test for multiple comparisons. Difference between groups was determined using the Student’s t-test. Survival analysis was performed using the Kaplan-Meier method, and differences in the survival curves were analyzed with the log-rank test. Univariate and multivariate Cox regression analyses were performed to determine prognostic factors for overall survival (OS), and recurrence-free survival (RFS). Hazard ratios (HRs) and confidence intervals (CI) were also calculated. Spearman correlation analysis was used to calculate the correlation between TINCR and ST6GAL1 expression. A two-tailed P-value < 0.05 was considered statistically significant. All data analyses were performed using SPSS 25.0 software (SPSS Inc., Chicago, IL), GraphPad Prism (version 8.0, GraphPad Software, Inc.), and R version 4.0.2.
Discussion
Emerging evidence showed that lncRNAs played a crucial regulatory role in various types of carcinomas. In this study, we proposed that TINCR was upregulated in HCC tissues and indicated a gloomy prognosis in HCC patients. TINCR acted as a ceRNA to sponge miR-195-3p to facilitate ST6GAL1 expression, strengthening NF-κB signaling pathway, leading to promotion in HCC cell progression and oxaliplatin resistance in vitro and vivo. Our evidence suggests that TINCR may be served as a prognostic biomarker and potential therapeutic target for HCC patients.
The clinical significance of TINCR was previously reported in several malignant tumors, including HCC [
17,
20]. However, our patient data showed that no correlation was found between TINCR expression and tumor size, tumor node metastasis, or vascular invasion. Excluding the possibility of individual particularity of the case, TINCR, independent of tumor stage-related factors, indicated the intrinsic malignant transformation of HCC cells, is of great significance. Besides, to our knowledge, for the first time, TINCR was found to be associated with oxaliplatin sensitivity in HCC. Accumulating evidence suggests that TINCR may be a promising prognostic biomarker to guide the development of personalized chemotherapies for HCC patients.
Accumulating evidence supports the existence of a typical interaction network involving ceRNAs [
21], that is, lncRNAs regulate miRNAs by competitively binding to their target sites on protein-coding mRNA molecules. Given that the localization of TINCR in HCC is in the cytoplasm, we confirmed the regulatory axis of TINCR/miR-195-3p/ST6GAL1. The carcinogenic role of miR-195-3p remains uncertain. It was reported as an oncogene in renal cell carcinoma [
22], but mostly played an anti-tumor role in various tumors. For example, miR-195-3p inhibited cervical cancer cell proliferation by targeting BCDIN3D [
23], and reversed CCL4-enhanced VEGF-C expression in Oral Squamous Cell Carcinoma [
24]. In HCC, miR-195-3p might be a critical negative modulator of UBE2I, leading to the restraint of metastasis [
25]. The inhibiting effect of miR-195-3p in HCC was consistent with our findings.
As a ceRNA, the function of lncRNAs depends on the miRNA target. In this study, we proved the ST6GAL1 was the downstream target molecule of TINCR. ST6GAL1 encodes a member of glycosyltransferase family 29, which is a type II membrane protein that catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates [
26]. Aberrant glycosylation is a universal feature of cancer cells, and ST6GAL1 is reported to be associated with aggressive, invasive disease with chemoresistance in numerous cancers [
19]. The signaling pathways activated by ST6GAL1 mostly focused on PI3K/Akt, HIF1α, and TGFβ signaling [
27‐
29]. Strengthened NF-κB signaling by ST6GAL1 in HCC could be supplementary evidence for enhancing progression and chemoresistance in cancer cells. To verify the specific activation way of p65, we used phosphorylation inhibitor (BAY 11–7085) to inhibit the p-IκBα. The p65 phosphorylation failed to be rescued by upregulating ST6GAL1 when the p-IκBα was blocked. (Fig. S
2I). However, whether NF-κB is the unique pathway mediated by TINCR to induce oxaliplatin resistance needs to be further elucidated, and the downstream regulatory molecules await deeper investigation. Moreover, recently, ST6GAL1 was proven to be a serum biomarker that identifies lenvatinib-susceptible FGF19-driven HCC. Therefore, whether TINCR is related to tyrosine kinase inhibitors treatment in HCC is worth exploring. Given the potential widespread impact of TINCR and its downstream molecules, an improved understanding of how TINCR mediated sialylation controls cancer cell biology may give new horizons to a range of HCC therapeutics.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.